ESPE Abstracts

Introduction/Background: Non-invasive prenatal testing (NIPT) represents a major development for families affected by rare monogenic conditions by facilitating early prenatal diagnosis without the risks associated with traditional more invasive methods. For most rare diseases NIPT is only available clinically for paternally-inherited variants. One exception is in GCK and HNF4A diabetes, where the detection of a maternally or paternally inheri...

Background: Normal neonates exhibit a transitional state of physiological hyperinsulinism (HI) during the first 2-3 days of life as an adaption from the fetal state. Prolonged, pathological HI can cause irreversible cerebral damage, if not avoided by early diagnosis and prompt treatment. We hypothesized that umbilical cord blood glucose, included in routine cord gas analysis, can be used as an ideal screening tool for pathological HI. We first aimed to establi...

Background: Congenital hyperinsulinism (cHI) is characterized by recurrent, persistent hypoglycemia due to dysregulated insulin secretion from dysfunctional pancreatic beta cells. Hypoglycemia in combination with hypoketonemia can cause irreparable brain damage including lifelong neurologic impairments, seizures, and death. Avoidance of life-threatening hypoglycemia around-the-clock via vigilant glucose monitoring and frequent interventions, places immense psy...

Background: Congenital hyperinsulinism (CHI) is a rare disease affecting neonates, infants, and children caused by dysregulated insulin secretion resulting in severe recurrent hypoglycemia. Early treatment is necessary to limit the risk of neurologic and developmental sequelae. Dasiglucagon is a glucagon analog (stable liquid formulation) suitable for continuous subcutaneous infusion shown to raise blood glucose in a dose-dependent manner. Result...

Background: In 2007, non-coding variants in the promoter of SLC16A1, a beta-cell disallowed gene, were reported as a novel genetic cause of exercise-induced hyperinsulinism (HI). In this study, three different promoter variants were identified in 13 affected individuals from three families. It was proposed that these variants caused MCT1, which is encoded by SLC16A1, to be inappropriately expressed in the pancreatic beta cells resulting in insulin secretion in...

Background: Congenital Hyperinsulinism (CHI) is a rare condition that represents a substantial burden to affected children, their families and the health service (~£3.5 million annually).1–3 CHI is demanding, unpredictable and requires constant hypervigilance to minimise the risk of neurodisability and death. Rapid technological advancements in continuous glucose monitoring (CGM) have revolutionised blood glucose management for children ...